Oral, injected or infused: what NAD research can compare

Separate molecule from route

An oral NR capsule, an NMN capsule and a compounded NAD injection are not three packages of the same intervention. The precursor, formulation, route and exposure pattern all matter. The useful comparison starts with an exact product description. Without it, words such as absorbed or direct can obscure the question that matters most: whether the chosen approach produces a worthwhile outcome in people like the intended customer.

What the oral studies contribute

Randomized oral precursor studies provide evidence on particular formulations and endpoints. For example, a dose-ranging NMN trial enrolled 80 healthy middle-aged adults for 60 days, with blood NAD as its primary objective and several secondary measures. That is evidence about oral NMN in a defined trial. It is not a study of NAD injected under the skin, nor proof of a long-term healthy-aging benefit.

What the infusion study contributes

The Grant infusion pilot followed plasma and urinary metabolism around one six-hour session. That design helps describe disposition of infused NAD. It did not directly compare an infusion with an oral precursor course or a home injection program. A consumer cannot fairly compare its percentage changes with a supplement trial and conclude that the route with the larger number is more effective. The outcomes, specimens and timing differ.

Why bypassing digestion is insufficient

A route can bypass the digestive tract without establishing better delivery to a relevant tissue or a superior health effect. Exposure is one link in a longer chain. To establish route superiority, a study should use a suitable direct comparison and measure outcomes that matter, alongside tolerability and practical burden. The persuasive-sounding claim that a route is more direct cannot substitute for that experiment.

Practical differences are still real

Capsules, self-injection and clinic infusion create different demands on time, handling, supplies and professional supervision. Those differences can be compared honestly even where comparative efficacy remains uncertain. For injectables, ask who prepares the medicine, what documentation accompanies the batch and how shipping or storage problems are addressed. FDA explains that compounded products do not undergo its premarket review of safety, effectiveness and quality.

Keep burden in the comparison

A format comparison should account for more than money. Appointment time, travel, handling, storage, supplies and the ability to reach appropriate support can all influence whether a service fits. Record these as concrete requirements rather than converting them into an invented scientific score. Someone may reasonably value convenience without claiming a clinical advantage.

Likewise, a more involved route should not create an obligation to keep purchasing simply because the setup took effort. A clear service agreement explains the review point and the process for ending renewal. Clinical suitability and commercial cancellation are related practical concerns, but they are separate decisions. Knowing both in advance makes the uncertainty easier to evaluate without presenting any format as the default answer.

Make a two-part comparison

First compare evidence: exact molecule, population, comparator, outcome and duration. Then compare service: total bill, recurring commitment, travel or appointment time, and the support available if something goes wrong. Keep unknowns visible in both lists. An expensive route may be more burdensome without being proven better; a convenient capsule can still make claims beyond its trials. Our format tool is designed to keep those distinctions readable.